JP7040798B2 - 非アルコール性脂肪性肝疾患を処置するための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオン - Google Patents

非アルコール性脂肪性肝疾患を処置するための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオン Download PDF

Info

Publication number
JP7040798B2
JP7040798B2 JP2019529165A JP2019529165A JP7040798B2 JP 7040798 B2 JP7040798 B2 JP 7040798B2 JP 2019529165 A JP2019529165 A JP 2019529165A JP 2019529165 A JP2019529165 A JP 2019529165A JP 7040798 B2 JP7040798 B2 JP 7040798B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
mixture
oral
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019529165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500868A (ja
JP2020500868A5 (enrdf_load_stackoverflow
Inventor
ラランサ， マリア ピラール ピスクエタ
ペデモンテ， マルク マルティネル
Original Assignee
ミノリックス セラピューティクス エセ．エレ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミノリックス セラピューティクス エセ．エレ． filed Critical ミノリックス セラピューティクス エセ．エレ．
Publication of JP2020500868A publication Critical patent/JP2020500868A/ja
Publication of JP2020500868A5 publication Critical patent/JP2020500868A5/ja
Application granted granted Critical
Publication of JP7040798B2 publication Critical patent/JP7040798B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2019529165A 2016-12-01 2017-12-01 非アルコール性脂肪性肝疾患を処置するための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオン Active JP7040798B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382584.7 2016-12-01
EP16382584 2016-12-01
PCT/IB2017/057587 WO2018100557A1 (en) 2016-12-01 2017-12-01 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease

Publications (3)

Publication Number Publication Date
JP2020500868A JP2020500868A (ja) 2020-01-16
JP2020500868A5 JP2020500868A5 (enrdf_load_stackoverflow) 2021-01-21
JP7040798B2 true JP7040798B2 (ja) 2022-03-23

Family

ID=57517838

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019529165A Active JP7040798B2 (ja) 2016-12-01 2017-12-01 非アルコール性脂肪性肝疾患を処置するための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオン

Country Status (20)

Country Link
US (1) US11938122B2 (enrdf_load_stackoverflow)
EP (1) EP3548026B1 (enrdf_load_stackoverflow)
JP (1) JP7040798B2 (enrdf_load_stackoverflow)
KR (1) KR102595034B1 (enrdf_load_stackoverflow)
CN (1) CN110022877B (enrdf_load_stackoverflow)
AU (1) AU2017370003B2 (enrdf_load_stackoverflow)
BR (1) BR112019011334A2 (enrdf_load_stackoverflow)
CA (1) CA3044364A1 (enrdf_load_stackoverflow)
CY (1) CY1124116T1 (enrdf_load_stackoverflow)
DK (1) DK3548026T3 (enrdf_load_stackoverflow)
EA (1) EA201991304A1 (enrdf_load_stackoverflow)
ES (1) ES2867300T3 (enrdf_load_stackoverflow)
HR (1) HRP20210576T1 (enrdf_load_stackoverflow)
HU (1) HUE054346T2 (enrdf_load_stackoverflow)
LT (1) LT3548026T (enrdf_load_stackoverflow)
MX (1) MX379710B (enrdf_load_stackoverflow)
PL (1) PL3548026T3 (enrdf_load_stackoverflow)
PT (1) PT3548026T (enrdf_load_stackoverflow)
SI (1) SI3548026T1 (enrdf_load_stackoverflow)
WO (1) WO2018100557A1 (enrdf_load_stackoverflow)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201991304A1 (ru) 2016-12-01 2019-12-30 Минорикс Терапьютикс С.Л. 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-дион для лечения неалкогольной жировой болезни печени
EP4545142A3 (en) 2018-06-06 2025-06-11 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
US20230172921A1 (en) 2020-04-30 2023-06-08 Minoryx Therapeutics S.L. Leriglitazone for treating lung inflammation and interstitial lung disease
EP4642456A1 (en) 2022-12-28 2025-11-05 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone
AU2024268104A1 (en) 2023-05-09 2025-11-27 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125285A1 (en) 2005-05-23 2006-11-30 K.U. Leuven Research And Development Insulin sensitization to slow down pubertal tempo and to augment pubertal growth
WO2015150476A1 (en) 2014-04-02 2015-10-08 Minoryx Therapeutics S.L. 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT68370A (en) * 1991-04-11 1995-06-28 Takeda Chemical Industries Ltd Thiazolidine derivatives, pharmaceutical compositions containing them and process for their production
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
WO1993022445A1 (en) 1992-05-05 1993-11-11 The Upjohn Company A process for producing pioglitazone metabolite
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
WO2003055485A1 (en) 2001-12-21 2003-07-10 Smithkline Beecham Corporation Dosing regimen for ppar-gamma activators
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
EP2902026B1 (en) 2006-03-16 2017-10-04 Metabolic Solutions Development Company LLC Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US20150224120A1 (en) 2011-09-14 2015-08-13 Catherine Clelland Compositions and methods for treating hyperprolinemia-associated mental disorders
US8865747B2 (en) 2012-03-23 2014-10-21 Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) Pioglitazone for use in the treatment of adrenoleukodystrophy
US20140178456A1 (en) 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
WO2014152843A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
WO2015109037A1 (en) 2014-01-15 2015-07-23 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
EA201991304A1 (ru) 2016-12-01 2019-12-30 Минорикс Терапьютикс С.Л. 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-дион для лечения неалкогольной жировой болезни печени

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125285A1 (en) 2005-05-23 2006-11-30 K.U. Leuven Research And Development Insulin sensitization to slow down pubertal tempo and to augment pubertal growth
WO2015150476A1 (en) 2014-04-02 2015-10-08 Minoryx Therapeutics S.L. 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Med. Chem.，1969年，39(26)，pp.5053-5063
Journal of Chromatography B，2014年，969，pp.219-223

Also Published As

Publication number Publication date
HRP20210576T1 (hr) 2021-05-28
AU2017370003A1 (en) 2019-06-06
AU2017370003B2 (en) 2023-04-13
KR102595034B1 (ko) 2023-10-26
US20200093812A1 (en) 2020-03-26
SI3548026T1 (sl) 2021-07-30
US11938122B2 (en) 2024-03-26
HUE054346T2 (hu) 2021-08-30
EA201991304A1 (ru) 2019-12-30
CA3044364A1 (en) 2018-06-07
EP3548026A1 (en) 2019-10-09
CY1124116T1 (el) 2022-05-27
KR20190086766A (ko) 2019-07-23
ES2867300T3 (es) 2021-10-20
WO2018100557A1 (en) 2018-06-07
MX379710B (es) 2025-03-11
PT3548026T (pt) 2021-04-22
PL3548026T3 (pl) 2021-08-23
LT3548026T (lt) 2021-05-25
DK3548026T3 (da) 2021-04-19
JP2020500868A (ja) 2020-01-16
CN110022877B (zh) 2023-06-23
EP3548026B1 (en) 2021-01-20
MX2019006066A (es) 2019-09-10
BR112019011334A2 (pt) 2019-10-15
CN110022877A (zh) 2019-07-16

Similar Documents

Publication Publication Date Title
JP7040798B2 (ja) 非アルコール性脂肪性肝疾患を処置するための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオン
US20130296237A1 (en) Use Of Chloroquine To Treat Metabolic Syndrome
CN103998035A (zh) 包含格列酮和nrf2激活剂的药物组合物
US20130150346A1 (en) Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
TW200918049A (en) Compounds useful as medicaments
JP7549344B2 (ja) 治療有効量の５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンを投与する方法
JP5679458B2 (ja) 内臓脂肪重量の低下剤
JP7510170B2 (ja) ５－［［４－［２－［５－アセチルピリジン－２－イル］エトキシ］ベンジル］－１，３－チアゾリジン－２，４－ジオンおよびその塩の使用
JP2021527049A (ja) ミトコンドリア性疾患の処置における使用のための５−［［４−［２−［５−（１−ヒドロキシエチル）ピリジン−２−イル］エトキシ］フェニル］メチル］−１，３−チアゾリジン−２，４−ジオンおよびその塩
EP2598142B1 (en) Diphenyl ether compounds for use in the treatment of liver disorders
KR102784482B1 (ko) 신경퇴행성 질환 및/또는 그것의 임상적 상태를 억제 및/또는 치료하기 위한 조성물 및 방법
EP2412705B1 (en) Novel therapeutic agent for cognitive impairment
HK40014768B (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]ph-enyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
HK40014768A (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]ph-enyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
HK40012325A (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease
EA040395B1 (ru) Применение 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-диона или его фармацевтически приемлемой соли для лечения неалкогольной жировой болезни печени и способ лечения или предупреждения неалкогольной жировой болезни печени
JP2014148474A (ja) Ｇｌｐ−１分泌促進剤
Chang et al. A Novel Polymorphic Form of Sodium Benzoate (Ω-NaBen): Improved Solubility, Stability, Central Nervous System Effects, and Antipsychotic Activities via D-Amino Acid Regulation
JP2021534141A (ja) アルコール使用障害の治療剤
HK1165792A (en) Novel therapeutic agent for cognitive impairment
HK1126125A (en) Remedy for diabetic

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220303

R150 Certificate of patent or registration of utility model

Ref document number: 7040798

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150